GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Net Income (Discontinued Operations)

Zydus Lifesciences (BOM:532321) Net Income (Discontinued Operations) : ₹230 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Zydus Lifesciences's Net Income (Discontinued Operations) for the three months ended in Mar. 2024 was ₹32 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹230 Mil.

Zydus Lifesciences Net Income (Discontinued Operations) Historical Data

The historical data trend for Zydus Lifesciences's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Net Income (Discontinued Operations) Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -680.00 22,457.00 -46.00 230.00

Zydus Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.00 -10.00 -10.00 218.00 32.00

Zydus Lifesciences Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹230 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zydus Lifesciences Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences (BOM:532321) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
BOM:500257 NSE:TORNTPHARM NSE:AUROPHARMA BOM:543904 NSE:ALKEM BOM:500124 NSE:DIVISLAB BOM:524494 BOM:532331 BOM:506943 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
ZYDUSLIFE:India
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Website
https://www.zyduslife.com
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines